Organisation paid for research Program year 2023 Source: CMS Open Payments

Napa Research Center

Neither a doctor nor a teaching hospital

Research payments

$1,623,464

14 payments

Through program year 2023, Napa Research Center is reported as receiving $1,623,464 in research payments, across 14 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$84,923	3
2022	Research	$771,826	4
2021	Research	$326,793	4
2020	Research	$411,654	2
2019	Research	$28,268	1

Breakdown

Who paid Research payments · program years 2019–2023

Horizon Therapeutics plc $1,623,464 14 payments

Studies the money was for Research payments · program years 2019–2023

Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $456,022 4 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $432,546 2 payments
A Phase 4, Open-Label Study of Krystexxa? (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $426,270 1 payment
A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $221,338 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Randomized Controlled Trial RCT $28,268 1 payment
A Phase 4 Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $22,725 1 payment
Hznp-Kry-407 $14,655 1 payment
A Phase 4, Multicenter, Open-Label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-Administered in Patients With Uncontrolled Gout Who Have Previously Received Pegloticase Monotherapy But Did Not Maintain A Serum Uric Acid Response $11,680 2 payments
A Study With Tepezza in Patients With Diffuse Cutaneous Systemic Sclerosis (Dcssc) $9,960 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.